Systems and methods to link cd40 signaling to antigen binding
US-2024052013-A1 · Feb 15, 2024 · US
Humanized pertussis antibodies and uses thereof
US9512204B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9512204-B2 |
| Application number | US-201514675514-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2015 |
| Priority date | Mar 31, 2014 |
| Publication date | Dec 6, 2016 |
| Grant date | Dec 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
First claim
Opening claim text (preview).
What is claimed is: 1. A humanized 1B7 antibody that binds a pertussis toxin protein, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6; and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12. 2. The humanized 1B7 antibody of claim 1 , wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO:3 and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO:11. 3. The humanized 1B7 antibody of claim 1 , wherein the antibody binds the pertussis toxin protein with a K D of 3 nM or lower. 4. A pharmaceutical composition comprising the humanized 1B7 antibody of claim 1 and a pharmaceutically acceptable excipient. 5. A method of treating a patient infected with Bordetella pertussis comprising administering to the patient an effective amount of the humanized 1 B7 antibody of claim 1 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antibacterial agents · CPC title
Antitussive agents · CPC title
- C07K16/1225Primary
from Bordetella (G) · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9512204B2 cover?
- The present invention relates to humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed to improved humanized 1B7 and 11E6 antibodies which bind the pertussis toxin protein.
- Who is the assignee on this patent?
- Univ Texas, Synthetic Biologics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1225. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).